Arlington Partners’s Cardlytics CDLX Stock Holding History

Arlington Partners’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8	Closed	-$5K	–	477
2021 Q4	$5K	Buy	+8	New	+$6.12K	﹤0.01%	564

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Arlington Partners's CDLX Position: Q1 2022 in Review

Arlington Partners sold out of Cardlytics (CDLX) in Q1 2022, closing a stake of 8 shares — an estimated $5K sold.

Arlington Partners first reported a position in CDLX in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 153 funds tracked by Wall St. Rank hold CDLX as of Q1 2022.

Arlington Partners reported no remaining Cardlytics position as of Q1 2022 after selling out during the quarter.
Arlington Partners sold 8 Cardlytics shares in Q1 2022, an estimated $5K.
Arlington Partners first reported a position in Cardlytics in Q4 2021 and held it in 1 quarter.
Arlington Partners's Cardlytics position peaked at $5K in Q4 2021.
153 funds tracked by Wall St. Rank held Cardlytics as of Q1 2022.

Based on Arlington Partners's 13F filing for Q1 2022, filed 14 Apr 2022.